A study evaluating deucravacitinib (Sotyktu) against icotrokinra and placebo for moderate-to-severe plaque psoriasis was published on 2025-01-01. The publication, titled "Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2)", details the findings of this comparative trial.
Background
Deucravacitinib (Sotyktu) is an oral medication investigated for the treatment of moderate-to-severe plaque psoriasis. This study compared its efficacy and safety profile against another investigational drug, icotrokinra, and a placebo in the management of this chronic inflammatory skin condition.
Trial design
The published research encompasses the ICONIC-ADVANCE 1 & 2 studies, which investigated treatments for participants with moderate-to-severe plaque psoriasis. These trials were designed to compare the effects of once-daily oral icotrokinra, once-daily oral deucravacitinib, and placebo. The objective was to assess the relative efficacy and safety of these agents in this patient population.
What this means
The publication of the ICONIC-ADVANCE 1 & 2 studies provides clinicians and researchers with detailed information regarding the comparative evaluation of deucravacitinib, icotrokinra, and placebo in the context of moderate-to-severe plaque psoriasis. While specific efficacy and safety outcomes are not detailed in the provided data, the availability of the full publication allows for a comprehensive understanding of the trial methodology and reported results. This contributes to the growing body of evidence for managing plaque psoriasis with targeted oral therapies.
Source
The information regarding this publication was sourced from PubMed. The article, titled "Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2)", was published on 2025-01-01 and is accessible via pubmed.ncbi.nlm.nih.gov.